In contrast, TR3 silencing significantly inhibited the proliferation of these prostate cancer cells (CWR22Rv1 and LNCaP) (Figure 6C, right; Figure S5B), which was confirmed using viability assays of TR3-knockdown CWR22Rv1 cells (Figure 6D). Here, NR4A1 is linked to prostate carcinoma.